Scientific narrative

Translating cancer immunology into practical immunotherapy strategy.

MIORG focuses on the biology behind checkpoint therapy response and resistance, with particular attention to immune function, patient stratification, and the role of dendritic cells in generating effective antitumor T-cell responses.

Scientific scope

Checkpoint therapy response prediction, dendritic-cell-centered resistance biology, rational combinations, and translational validation.

Clinical context

Immune checkpoint therapy transformed oncology.

Anti-PD1 and anti-PD-L1 therapies changed the treatment landscape by enabling durable responses in selected patients across multiple tumor types. These agents remain among the most consequential advances in immuno-oncology and continue to shape how modern cancer treatment is designed.

Why this matters

Checkpoint therapy created a new therapeutic foundation, but it also exposed a persistent problem: powerful treatments still require better prediction and better combination logic to serve more patients.

Why resistance remains a major challenge

A meaningful proportion of patients do not respond to checkpoint blockade. Existing tools such as immunohistochemistry markers and tumor mutational burden can offer partial signal, but they may not be sufficient on their own for confident patient selection or clinical planning.

  • Uncertain therapeutic benefit for selected patients
  • Potential exposure to adverse events without corresponding response
  • Risk of delayed transition to alternative treatment strategies

Resistance themes

Immune escape Antigen presentation T-cell priming Patient selection

MIORG frames resistance as a tractable biological and translational problem.

Dendritic cell biology

Dendritic cells and antitumor T-cell generation.

Dendritic cells are central to antigen presentation and to the generation of new antitumor T-cell responses. When tumors suppress these processes, checkpoint inhibition alone may be insufficient. MIORG’s therapeutic thinking therefore centers on restoring or protecting critical antigen-presenting function in resistant settings.

A

Antigen presentation

Dendritic cells help convert tumor-derived information into productive immune activation.

B

T-cell generation

New antitumor T-cell responses are essential for durable immune control in resistant settings.

C

Therapeutic restoration

MIORG’s antibody strategy is designed to restore this pathway in combination-oriented development.

Immune response prediction

Predictive immune profiling.

Response prediction benefits from a multidimensional view of tumor and immune context. MIORG’s predictive profiling approach is designed around immune functional RNA/DNA profiling, integrating a focused immune-related gene signature with tumor mutational burden to improve response prediction for anti-PD1/PD-L1 therapies.

  • Immune-related gene signature designed for clinically relevant stratification
  • Integration with tumor mutational burden rather than single-marker dependence
  • Support for more informed patient routing and alternative care discussions

Translational intent

Predictive profiling is positioned not as an isolated dataset exercise, but as a tool for real-world oncology decision support and partnership-led development.

Combination strategy

Rational combination therapies.

Combination development in immuno-oncology is strongest when it follows mechanism. MIORG’s therapeutic programs are shaped around the biology of immune resistance, particularly where dendritic-cell impairment may limit the impact of checkpoint blockade alone.

Combination logic

Programs are designed to complement checkpoint therapy rather than simply add another agent.

Preclinical validation

Development emphasis is on resistant tumor models and careful mechanistic interpretation.

Partner relevance

Combination candidates can align with broader biomarker, translational, and co-development discussions.

Discovery-to-validation

Discovery-to-validation model.

Discovery biology

Define resistance mechanisms, immune signatures, and tractable intervention points.

Functional immunology

Use biologically grounded assays to test immune activity, dendritic cell function, and combination logic.

Preclinical models

Evaluate programs in resistant tumor contexts to refine development and partnering hypotheses.

Clinical integration

Translate insights into patient stratification, validation pathways, and collaboration-ready programs.